BPC-157 angiogenesis research: VEGFR2 and nitric oxide in lab studies
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Not approved. BPC-157 is not FDA-approved for any use and is prohibited at all times under the WADA anti-doping code. See our legal status file.
Search for "BPC-157 angiogenesis" and two opposite stories appear. One presents new blood vessel growth as the reason the peptide is promoted online for tissue repair. The other reads vessel growth as a warning sign. Both stories draw on the same small set of preclinical papers.
This explainer looks at what those papers measured: receptor activity in cultured endothelial cells, vessel sprouting on chick embryo membranes, and blood flow in rodent limbs. It also sets out what such readouts can and cannot tell anyone about people. For the wider set of proposed pathways, see our BPC-157 mechanism overview. For the full evidence base, see our evidence guide.
What "angiogenesis" means in a lab paper
Angiogenesis is the formation of new capillaries from existing blood vessels. Endothelial cells line the inside of vessels and respond to growth signals, chiefly vascular endothelial growth factor (VEGF). VEGF acts mainly through a receptor on the cell surface called VEGFR2.
Laboratories cannot watch angiogenesis happen inside a person. Instead they measure proxies:
cell migration
the formation of tube-like structures on a gel
vessel counts in tissue sections
blood flow imaging in animals
Each proxy captures one slice of a complex process. None is a direct measure of how vessels behave in a living human.
The 2017 VEGFR2 study: what was measured
The most frequently cited angiogenesis paper is Hsieh and colleagues (2017). Its title describes BPC-157 as pro-angiogenic and links that activity to "VEGFR2 activation and up-regulation" [1]. It came from a different author group than the Zagreb team that produced most of the BPC-157 literature. The paper combined several assay types, and each needs to be read on its own terms.
VEGFR2 expression and internalization
The authors reported higher VEGFR2 levels in endothelial cells and in rat tissue exposed to BPC-157 [1]. They also examined receptor internalization, meaning movement of the receptor from the cell surface into the cell. Internalization is a normal step after a receptor is activated, so researchers use it as an index of signalling activity. It is a molecular event measured in a dish, usually with fluorescent labelling and microscopy. It shows that a signal was triggered. It does not show what that signal does to a whole organism over time.
The VEGFR2-Akt-eNOS phosphorylation chain
When VEGFR2 is activated, it passes the signal on by adding phosphate groups to downstream proteins. Two of these are Akt and endothelial nitric oxide synthase (eNOS), the enzyme that makes nitric oxide in vessel walls. The 2017 paper reported increased phosphorylation along this VEGFR2-Akt-eNOS chain [1]. Phosphorylation is typically detected with antibodies on protein blots. It is a snapshot of signalling at chosen time points and concentrations, not a measure of tissue function.
The chick chorioallantoic membrane (CAM) assay
The CAM assay uses the membrane that surrounds a developing chick embryo inside a fertilised egg. A test substance is placed on the membrane, and researchers later count or score the branching vessels. Hsieh and colleagues reported more vessel formation in this model [1]. The CAM assay is fast and inexpensive, which is why it is popular. Its limits are also clear: the tissue is embryonic, the immune system is immature, and a chick is not a mammal.
The rat hind limb ischaemia model
In this model, blood supply to one hind limb of a rat is surgically interrupted. Researchers then track how blood flow returns, usually with laser Doppler imaging, and count vessels in the muscle. The 2017 paper reported faster restoration of flow and higher vessel density in animals given BPC-157 than in controls [1]. This is the closest of the four assays to a functional outcome. It is still a short-term experiment in young, otherwise healthy rodents with an acute surgical injury.
The nitric oxide thread
Nitric oxide runs through much of the BPC-157 literature. A 2014 review from the originating group summarised rodent experiments that paired BPC-157 with L-NAME, a drug that blocks nitric oxide production, and with L-arginine, the raw material for nitric oxide [2]. The authors reported that BPC-157 interacted with the effects of both. They interpreted this as a relation to the nitric oxide system as a whole.
A 2025 commentary by the same group goes further. It argues that BPC-157 targets the "cytotoxic and damaging actions" of angiogenesis and nitric oxide while "maintaining, promoting, or recovering their essential protective functions" [3]. This is a hypothesis put forward by the researchers most invested in the compound. It is not a measured outcome. A separate review from that group on wound healing describes vessel formation as one component it observed in rodent wound models [4].
How we weigh claims from a single originating group is explained on our about page.
Why angiogenesis is a double-edged readout
More vessels are not automatically a good result. Basic vascular biology links angiogenesis both to normal tissue repair and to disease processes, including tumour growth and some eye and inflammatory conditions. A pro-angiogenic signal in a dish is therefore neither reassuring nor alarming on its own. It is a question that the experiment has not yet answered.
The preclinical papers above leave several of those questions open:
Selectivity. Does the signal appear only in injured tissue, or everywhere the compound reaches?
Duration. Do the new vessels mature and stabilise, or regress? What happens with prolonged exposure?
Pre-existing disease. No paper in our source list tested vascular effects in animals carrying tumours or with diabetic eye disease.
Replication. Key findings rest on single studies, mostly from one research network.
Tendon is a tissue with a sparse blood supply, which is one reason vessel signals appear in rodent tendon work. Our page on BPC-157 tendon research covers those experiments. For a broader view of what rodent models can and cannot show, see BPC-157 animal studies.
What human research exists, and what it does not cover
A 2025 systematic review in orthopaedic sports medicine described the BPC-157 evidence base as predominantly preclinical. It also noted that the compound lacks FDA approval and is banned in professional sports [5]. A 2026 systematic review set out specifically to collect the human evidence on efficacy and safety in orthopaedic and regenerative settings [6].
The individual human reports in our source list are very small:
a retrospective report on knee pain [7]
a pilot study that looked at safety measures after intravenous infusion in a handful of adults [8]
Neither was a vascular study. Neither imaged vessel growth, measured VEGFR2 signalling, or included a randomised comparison group. No human trial of BPC-157's vascular effects appears in the published record we reviewed. Every statement about BPC-157 and angiogenesis in people is therefore an extrapolation from cells, eggs and rodents.
Regulators have reached a cautious position:
FDA. The agency lists BPC-157 among bulk drug substances for compounding that may present significant safety risks [9]. Its Pharmacy Compounding Advisory Committee met in July 2026 to consider substances including BPC-157 [10].
WADA. BPC-157 is on WADA's Prohibited List [11].
Our legal status file has the dated detail.
How to read an angiogenesis claim
When an article cites BPC-157 and blood vessels, five questions sort the evidence quickly:
What model was used? Cell culture, chick membrane or rodent?
What was measured? A phosphorylation band, a vessel count or blood flow?
Who ran the study? Was it the originating group or an independent team?
Has the finding been replicated?
Were any human vascular outcomes measured at all?
Our checklist for evaluating BPC-157 studies expands on each point.
Further reading: choosing a cell signalling or pharmacology textbook
Methods sections on receptor signalling assume familiarity with kinases, protein blots, endothelial cell culture and vascular imaging. A solid general textbook makes these papers far easier to follow and to judge critically.
When comparing options, these criteria matter more than cover blurbs:
Edition date. Signalling biology moves quickly, so recent editions cover receptor trafficking and nitric oxide biology in more depth.
Methods coverage. Look for chapters that explain assays, not only pathways.
Figure quality. Clear pathway diagrams save hours.
Format. Searchable ebooks suit reference use, while print often suits sustained study.
Price transparency. Compare new, used and rental pricing, and check whether online companion material requires a separate code.
University library copies and earlier editions are an inexpensive way to check whether a book's level and style suit a reader before paying full price. Many publishers also post sample chapters online.
Selection here is based on the criteria above, not on commission rates. Any title we list can be checked against a library catalogue first.
Frequently asked questions
Has BPC-157 been shown to cause angiogenesis in humans?
No. The angiogenesis findings come from cultured cells, chick embryo membranes and rodent models [1]. No human study in the published record we reviewed measured vessel growth or VEGFR2 signalling.
Does a pro-angiogenic signal mean BPC-157 is unsafe?
The lab data cannot settle that either way. Angiogenesis is involved in normal repair and in disease processes. None of the cited studies tested vascular effects over long periods or in animals with existing tumours. FDA has listed BPC-157 among compounding substances that may present significant safety risks [9].
Why do researchers use the chick CAM assay?
It is fast, cheap and makes vessel branching easy to see and count. Its tissue is embryonic and non-mammalian, so results are an early screening signal rather than a prediction of human effects.
Where does nitric oxide fit in?
eNOS sits downstream of VEGFR2 and produces nitric oxide in vessel walls [1]. The originating group has published rodent work and commentary proposing a broader BPC-157 relation to the nitric oxide system [2][3]. That proposal has not been tested in people.
Related on this site
Last updated: 23 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.
Sources
Read next
How to evaluate a BPC-157 study: a reader's checklist and reading list
A five-question checklist for reading BPC-157 studies, applied to the three human reports and two systematic reviews, plus a labelled reading list on evidence appraisal.
Sports wearables buyer's guide: GPS watches, chest straps, trackers
How to compare wearables for athletes: what GPS watches, chest straps and activity trackers measure, which figures are estimates, and how to weigh battery, data export, privacy and price.
BPC-157 vs TB-500: the evidence and regulatory records compared
Two peptides, one thin record. How BPC-157 and TB-500 compare on human evidence, FDA's July 2026 compounding review and WADA's Prohibited List, with every unverified claim flagged.